[go: up one dir, main page]

CL2011002381A1 - Uso de saxagliptina para la reduccion del riesgo de muerte en un humano cuasado por un evento cardiovascular tal como un infarto al miocardio, ictus no fatal, muerte cadiovascular - Google Patents

Uso de saxagliptina para la reduccion del riesgo de muerte en un humano cuasado por un evento cardiovascular tal como un infarto al miocardio, ictus no fatal, muerte cadiovascular

Info

Publication number
CL2011002381A1
CL2011002381A1 CL2011002381A CL2011002381A CL2011002381A1 CL 2011002381 A1 CL2011002381 A1 CL 2011002381A1 CL 2011002381 A CL2011002381 A CL 2011002381A CL 2011002381 A CL2011002381 A CL 2011002381A CL 2011002381 A1 CL2011002381 A1 CL 2011002381A1
Authority
CL
Chile
Prior art keywords
death
cadiovascular
saxagliptin
risk
reduce
Prior art date
Application number
CL2011002381A
Other languages
English (en)
Inventor
Robert Edelberg Jay Fiedorek Fred Frederich
Original Assignee
Astrazeneca Uk Ltd
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42199886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002381(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Ltd, Astrazeneca Ab filed Critical Astrazeneca Uk Ltd
Publication of CL2011002381A1 publication Critical patent/CL2011002381A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2011002381A 2009-03-27 2011-09-27 Uso de saxagliptina para la reduccion del riesgo de muerte en un humano cuasado por un evento cardiovascular tal como un infarto al miocardio, ictus no fatal, muerte cadiovascular CL2011002381A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16415309P 2009-03-27 2009-03-27
US16539909P 2009-03-31 2009-03-31

Publications (1)

Publication Number Publication Date
CL2011002381A1 true CL2011002381A1 (es) 2012-03-23

Family

ID=42199886

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002381A CL2011002381A1 (es) 2009-03-27 2011-09-27 Uso de saxagliptina para la reduccion del riesgo de muerte en un humano cuasado por un evento cardiovascular tal como un infarto al miocardio, ictus no fatal, muerte cadiovascular

Country Status (15)

Country Link
US (1) US20100256153A1 (es)
EP (1) EP2411005A1 (es)
JP (1) JP2012522015A (es)
KR (1) KR20110135411A (es)
CN (1) CN102448456A (es)
AU (1) AU2010229653A1 (es)
BR (1) BRPI1013500A2 (es)
CA (1) CA2756786A1 (es)
CL (1) CL2011002381A1 (es)
EA (1) EA201101231A1 (es)
IL (1) IL214991A0 (es)
MX (1) MX2011009852A (es)
SG (2) SG10201501882TA (es)
WO (1) WO2010111665A1 (es)
ZA (1) ZA201106756B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968344A1 (en) * 2013-03-15 2016-01-20 Boehringer Ingelheim International GmbH Use of linagliptin in cardio- and renoprotective antidiabetic therapy
KR101598612B1 (ko) * 2013-08-29 2016-02-26 재단법인 아산사회복지재단 Dpp-4 억제제를 포함하는 혈관 또는 심장판막 석회화의 예방 또는 치료용 조성물
EA201790526A1 (ru) * 2014-09-05 2017-06-30 Сановель Илач Санайи Ве Тиджарет А.Ш. Фармацевтические комбинации ситаглиптина
CN113209295A (zh) * 2015-02-27 2021-08-06 财团法人峨山社会福祉财团 含有dpp-4抑制剂的用于预防或治疗瓣膜钙化的组合物
US20180140747A1 (en) * 2015-04-15 2018-05-24 ConcieValve LLC Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
JP7096598B2 (ja) * 2016-09-07 2022-07-06 トラスティーズ オブ タフツ カレッジ イムノｄａｓｈ阻害剤及びｐｇｅ２アンタゴニストを用いた併用療法
GB201619861D0 (en) * 2016-11-24 2017-01-11 Narodden Salomon Treatments for heart failure and cardiac ischaemic reperfusion injury
US11559537B2 (en) 2017-04-07 2023-01-24 Trustees Of Tufts College Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists
US20230241064A1 (en) * 2020-01-08 2023-08-03 Resverlogix Corp. Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a dipeptidyl peptidase 4 inhibitor

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (es) 1974-06-07 1981-03-18
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
JPS62501009A (ja) 1984-12-04 1987-04-23 サンド・アクチエンゲゼルシヤフト メバロノラクトンのインデン同族体及びその誘導体
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
WO1987002662A2 (en) 1985-10-25 1987-05-07 Sandoz Ag Heterocyclic analogs of mevalonolactone and derivatives thereof, processes for their production and their use as pharmaceuticals
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
GB2205837B (en) 1987-05-22 1991-11-20 Squibb & Sons Inc Phosphorus-containing hmg-coa reductase inhibitors
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en) 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9209628D0 (en) 1992-05-05 1992-06-17 Smithkline Beecham Plc Compounds
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5662934A (en) 1993-01-05 1997-09-02 Najarian; Thomas Compositions and methods for lowering cholesterol while maintaining antioxidant levels
DE69324504T2 (de) 1993-01-19 1999-08-26 Warner-Lambert Co. Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5698527A (en) 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
ATE344279T1 (de) 1995-12-13 2006-11-15 Univ California Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors
IL117702A0 (en) 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
DE19622222A1 (de) 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
AU2401697A (en) 1996-06-20 1998-01-07 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
CZ302475B6 (cs) 1997-10-08 2011-06-08 Sankyo Company Limited Substituované kumulované heterocyklické slouceniny
TR200100149T2 (tr) 1998-07-06 2001-10-22 Bristol-Myers Squibb Company Dual anjiyotensin endotelin alıcı antagonistleri olarak bifenil-sülfonamitler
WO2000015201A2 (en) 1998-09-10 2000-03-23 Forbes Medi-Tech Inc. Compositions comprising one or more phytosterols, phytostanols or mixtures of both and one or more alpha, beta, delta, or gamma tocotrienols or derivatives thereof and use of the compositions in treating or preventing cardiovascular disease, its underlying conditions and other disorders
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
JP2002530347A (ja) 1998-11-25 2002-09-17 ニュートリ・ファーマ・アルメント・アクシェセルスカブ 大豆蛋白質、食物繊維およびフィトエストロゲン化合物を含む組成物、および心臓血管疾患の予防および／または治療におけるその使用
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
AU776785B2 (en) 1999-02-24 2004-09-23 Johns Hopkins University, The Compositions and methods for modulating serum cholesterol
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7244727B2 (en) 2002-11-22 2007-07-17 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
US7420079B2 (en) * 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
WO2005049022A2 (en) * 2003-11-17 2005-06-02 Novartis Ag Use of dipeptidyl peptidase iv inhibitors
TW200536827A (en) * 2004-05-04 2005-11-16 Bristol Myers Squibb Co Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
US7214702B2 (en) * 2004-05-25 2007-05-08 Bristol-Myers Squibb Company Process for producing a dipeptidyl peptidase IV inhibitor
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
JP2008506651A (ja) * 2004-07-14 2008-03-06 ノバルティス アクチエンゲゼルシャフト Ｄｐｐ−ｉｖ阻害剤と５−ｈｔ３および／または５−ｈｔ４受容体を調節する化合物の組合せ剤
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
EP1802308A1 (en) * 2004-10-08 2007-07-04 Novartis AG Combination of organic compounds
JP2008516978A (ja) 2004-10-15 2008-05-22 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満症の処置のためのビフェニル−４−イル−カルボニルアミノ酸誘導体の製造および使用
WO2006082010A1 (en) 2005-02-07 2006-08-10 F.Hoffmann-La Roche Ag Inhibitors of diacylglycerol acyltransferase (dgat)
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
CN101208085B (zh) * 2005-06-10 2011-01-05 诺瓦提斯公司 1-[(3-羟基-金刚烷基-1-基氨基)-乙酰基]-吡咯烷基-2(s)-腈的调释制剂
AU2006258917A1 (en) 2005-06-11 2006-12-21 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
US20080200510A1 (en) * 2005-07-12 2008-08-21 Smiljana Milosavljevic-Ristic Combination of Organic Compounds
PE20090696A1 (es) * 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas

Also Published As

Publication number Publication date
EP2411005A1 (en) 2012-02-01
IL214991A0 (en) 2011-11-30
AU2010229653A1 (en) 2011-10-20
CN102448456A (zh) 2012-05-09
ZA201106756B (en) 2013-02-27
MX2011009852A (es) 2011-09-29
SG10201501882TA (en) 2015-06-29
SG174504A1 (en) 2011-10-28
EA201101231A1 (ru) 2012-06-29
WO2010111665A1 (en) 2010-09-30
KR20110135411A (ko) 2011-12-16
BRPI1013500A2 (pt) 2016-04-05
JP2012522015A (ja) 2012-09-20
US20100256153A1 (en) 2010-10-07
CA2756786A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
CL2011002381A1 (es) Uso de saxagliptina para la reduccion del riesgo de muerte en un humano cuasado por un evento cardiovascular tal como un infarto al miocardio, ictus no fatal, muerte cadiovascular
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
CU24336B1 (es) Compuestos de imidazopirrolidinona
MX2013005407A (es) 5-halopirazolcarboxamidas.
DK2632589T3 (da) Carbonhydridomdannelseskatalysatorsammensætning
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
DK3195793T3 (da) Forbedringer i eller relateret til oftalmologi
BR112013000600A2 (pt) proteção de face para ser fixada a um capacete de proteção, particularmente para engenheiros florestais
ECSP11010905A (es) Uso de ditiina-tetracarboximidas para combatir hongos fitopatógenos
BRPI1013356A8 (pt) uso de agentes tensoativos carregados para a redução da mancha em tecidos devido aos antitranspirantes
DOP2013000307A (es) Antagonistas de trpv4
DK3045164T3 (da) Vandige farmaceutiske sammensætninger, der indeholder borat-polyol-komplekser
SMT202000522T1 (it) Composizioni farmaceutiche per uso topico a base di acido ialuronico solfatato come promotore dell'assorbimento cutaneo
HN2011003403A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
ECSP14013327A (es) Compuestos con actividad nematicida
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
IT1396692B1 (it) Struttura di protesi per amputati agli arti inferiori.
EP2845602A4 (en) CYCLOSPORINE-CONTAINING NON-REFRESHING OPHTHALMIC NANOEMULSION COMPOSITION
DOP2015000076A (es) Benzamidas
IL227398A0 (en) Disialyllacto-n-tetraose (dslnt) or variants, isomers, analogs and derivatives thereof for the prevention or delay of intestinal disease
EP2517681A4 (en) PORTABLE ARTICLE
BR112012020555A2 (pt) composições líquidas antimicrobianas.
ECSP11011473A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5- disustituída
BR112015011759A2 (pt) composição simbiótica e uso da mesma
CL2013003651A1 (es) Uso de una composición que comprende un antagonista del receptor de quimiocina c-c tipo 5 (ccr5) para preparar un medicamento útil para tratar una infección por staphylococcus aureus, donde dicha infección por s. aureus es causada por una cepa de s. aureus que expresa luke/d.